£»42£¨2£©£º196-200
19)
Fleckenstein, A£®et al£®£ºBayer-SymposiumIX Cardiovascular effects of dihydropyridine-type calcium antagonist and agonist 1985£»480-499
20)
Kazda, S£®et al£®£ºAsian Pacific Adalat-Symposium£®New Therapy of Ischemic Heart Disease and Hypertension 1983£»50-62
21)
ÈýСÌïÉìÖ®¡¡Ëû£ºÈÕËaÀíÕI 1999£»114£º373-382
22)
´¨Ô¹«ÒŽ¡¡Ëû£ºÈÕËaÀíÕI 1988£»92£¨6£©£º397-410
23)
ƽ¡¡„t·ò¡¡Ëû£ºArzneim-Forsch£®/Drug Res£®1986£»36£¨1£©:35-39
24)
Œm›g¡¡¹¦¡¡Ëû£ºÃ}¹Üѧ 1989£»29£¨6£©£º471-474
25)
Kawashima, Y, et al£®£ºJ£®Physiol£®1988£»402£º219-235
26)
Bean B£®P£®et al£®£ºCirc£®Res£®1986£»59£¨2£©£º229-235
**,*ÎÄÏ×ÕˆÇóÏÈ
Ö÷ÒªÎÄÏפËÓ›Ýd¤ÎÉçÄÚÙYÁϤˤĤ¤Þ¤·¤Æ¤âÏÂÓ›¤Ë¤´ÕˆÇóϤµ¤¤£®
ÌïÞxÈýÁâÑuËaÖêʽ»áÉç¡¡¤¯¤¹¤êÏàÕ„¥»¥ó¥¿©`
¨“541-8505¡¡´óÚæÊÐÖÐÑëÇøµÀÐÞî®3-2-10
ëŠÔ’0120-753-280
ÑuÔìØœ‰Ó˜IÕߵȤÎÊÏÃûÓÖ¤ÏÃû³Æ¼°¤ÓסËù
**,*ÑuÔìØœ‰ÓÔª
ÌïÞxÈýÁâÑuËaÖêʽ»áÉç
´óÚæÊÐÖÐÑëÇøµÀÐÞî®3-2-10
ÌáЯ
Bayer HealthCare AG,Germany
¥Ð¥¤¥í¥Æ¥ó¥·¥ó£¬Baylotensin¤ÏBayer AG£¬GermanyµÇåhÉ̘Ë
ÒÔÏÂÊÇ¡°È«ÇòÒ½Ò©¡±Ïêϸ×ÊÁÏ |
|
|